review · Infection and Drug Resistance
This review examines the conflicting evidence surrounding the use of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in the context of COVID-19. While some animal studies suggested these drugs could help prevent or treat the effects of COVID-19 infection, other findings indicated they might worsen the infection's deleterious conditions. This creates a paradoxical situation, highlighting the need for extensive further investigation. The review concludes that more research is required to establish the efficacy and conduct a benefit-risk analysis of ACEIs/ARBs during COVID-19, particularly for patients with comorbidities such as hypertension, heart failure, and renal disease linked to diabetes.
This research is important because it addresses a critical question about the safety and effectiveness of commonly prescribed medications, ACEIs and ARBs, for patients with COVID-19. Clarifying their role is vital for guiding clinical decisions and ensuring optimal care, especially for individuals with pre-existing health conditions.
The abstract does not indicate an application pathway. It highlights a need for further research to clarify the role of existing drugs in a specific disease context. This is early-stage research focused on understanding drug interactions rather than developing new products or services, and it is far from real-world use.
AI-generated from the published abstract. Always read the original work before citing.
Although some animal studies suggested that the use of ACEIs/ARBs could contribute for the prevention and treatment of the effects of the COVID-19 infection, there are also contradictory scenarios indicating that their use may exacerbate the deleterious conditions of the infection. As a result of the paradoxical issue of using ACEIs/ARBs during COVID-19, it is still an area requiring extended investigation to prove. Additionally, a trial evidence of their efficacy and the possible benefit risk analysis of these conventional drugs during COVID-19 in connection with other comorbidities like hypertension, heart failure, and renal disease associated with diabetes should also be addressed.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2147/idr.s264882
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
